FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382774814> ?p ?o ?g. }

• W4382774814 endingPage "3593" @default.
• W4382774814 startingPage "3577" @default.
• W4382774814 abstract "Triple-negative breast cancer (TNBC) is a highly aggressive subtype with a poor prognosis. Current single-agent checkpoint therapy has limited effectiveness in TNBC patients. In this study, we developed doxorubicin-loaded platelet decoys (PD@Dox) for chemotherapy and induction of tumor immunogenic cell death (ICD). By combining PD-1 antibody, PD@Dox has the potential to enhance tumor therapy through chemoimmunotherapy in vivo.Platelet decoys were prepared using 0.1% Triton X-100 and co-incubated with doxorubicin to obtain PD@Dox. Characterization of PDs and PD@Dox was performed using electron microscopy and flow cytometry. We evaluated the properties of PD@Dox to retain platelets through sodium dodecyl sulfate-polyacrylamide gel electrophoresis, flow cytometry, and thromboelastometry. In vitro experiments assessed drug-loading capacity, release kinetics, and the enhanced antitumor activity of PD@Dox. The mechanism of PD@Dox was investigated through cell viability assays, apoptosis assays, Western blot analysis, and immunofluorescence staining. In vivo studies were performed using a TNBC tumor-bearing mouse model to assess the anticancer effects.Electron microscopic observations confirmed that platelet decoys and PD@Dox exhibited a round shape similar to normal platelets. Platelet decoys demonstrated superior drug uptake and loading capacity compared to platelets. Importantly, PD@Dox retained the ability to recognize and bind tumor cells. The released doxorubicin induced ICD, resulting in the release of tumor antigens and damage-related molecular patterns that recruit dendritic cells and activate antitumor immunity. Notably, the combination of PD@Dox and immune checkpoint blockade therapy using PD-1 antibody achieved significant therapeutic efficacy by blocking tumor immune escape and promoting ICD-induced T cell activation.Our results suggest that PD@Dox, in combination with immune checkpoint blockade therapy, holds promise as a potential strategy for TNBC treatment." @default.
• W4382774814 created "2023-07-02" @default.
• W4382774814 creator A5008932652 @default.
• W4382774814 creator A5018571693 @default.
• W4382774814 creator A5024534066 @default.
• W4382774814 creator A5030429211 @default.
• W4382774814 creator A5071605336 @default.
• W4382774814 date "2023-06-01" @default.
• W4382774814 modified "2023-10-18" @default.
• W4382774814 title "Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model" @default.
• W4382774814 cites W2035174480 @default.
• W4382774814 cites W2067632426 @default.
• W4382774814 cites W2089026309 @default.
• W4382774814 cites W2103099575 @default.
• W4382774814 cites W2118605519 @default.
• W4382774814 cites W2174295196 @default.
• W4382774814 cites W2339017415 @default.
• W4382774814 cites W2412688330 @default.
• W4382774814 cites W2807930584 @default.
• W4382774814 cites W2886835124 @default.
• W4382774814 cites W2889746019 @default.
• W4382774814 cites W2897826078 @default.
• W4382774814 cites W2911264664 @default.
• W4382774814 cites W2911718257 @default.
• W4382774814 cites W2913935991 @default.
• W4382774814 cites W2916784537 @default.
• W4382774814 cites W2924762495 @default.
• W4382774814 cites W2963949067 @default.
• W4382774814 cites W2990398119 @default.
• W4382774814 cites W3006693642 @default.
• W4382774814 cites W3008818246 @default.
• W4382774814 cites W3012757688 @default.
• W4382774814 cites W3043060468 @default.
• W4382774814 cites W3043135743 @default.
• W4382774814 cites W3091196869 @default.
• W4382774814 cites W3138073397 @default.
• W4382774814 cites W3170638641 @default.
• W4382774814 cites W3204026743 @default.
• W4382774814 cites W3217059543 @default.
• W4382774814 cites W4207004596 @default.
• W4382774814 cites W4220749381 @default.
• W4382774814 cites W4281752176 @default.
• W4382774814 cites W4283793441 @default.
• W4382774814 cites W4286562033 @default.
• W4382774814 cites W4295469327 @default.
• W4382774814 cites W4297983164 @default.
• W4382774814 cites W4298626978 @default.
• W4382774814 cites W4302010920 @default.
• W4382774814 cites W4307423139 @default.
• W4382774814 cites W4307425457 @default.
• W4382774814 cites W4308370248 @default.
• W4382774814 cites W4308722513 @default.
• W4382774814 cites W4309910679 @default.
• W4382774814 cites W4310433635 @default.
• W4382774814 cites W4311670295 @default.
• W4382774814 cites W4312224855 @default.
• W4382774814 doi "https://doi.org/10.2147/ijn.s403339" @default.
• W4382774814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37409026" @default.
• W4382774814 hasPublicationYear "2023" @default.
• W4382774814 type Work @default.
• W4382774814 citedByCount "0" @default.
• W4382774814 crossrefType "journal-article" @default.
• W4382774814 hasAuthorship W4382774814A5008932652 @default.
• W4382774814 hasAuthorship W4382774814A5018571693 @default.
• W4382774814 hasAuthorship W4382774814A5024534066 @default.
• W4382774814 hasAuthorship W4382774814A5030429211 @default.
• W4382774814 hasAuthorship W4382774814A5071605336 @default.
• W4382774814 hasBestOaLocation W43827748141 @default.
• W4382774814 hasConcept C121608353 @default.
• W4382774814 hasConcept C126322002 @default.
• W4382774814 hasConcept C150903083 @default.
• W4382774814 hasConcept C203014093 @default.
• W4382774814 hasConcept C207001950 @default.
• W4382774814 hasConcept C2776694085 @default.
• W4382774814 hasConcept C2777701055 @default.
• W4382774814 hasConcept C2780110267 @default.
• W4382774814 hasConcept C2780790343 @default.
• W4382774814 hasConcept C2781303535 @default.
• W4382774814 hasConcept C502942594 @default.
• W4382774814 hasConcept C530470458 @default.
• W4382774814 hasConcept C553184892 @default.
• W4382774814 hasConcept C71924100 @default.
• W4382774814 hasConcept C86803240 @default.
• W4382774814 hasConcept C8891405 @default.
• W4382774814 hasConcept C89560881 @default.
• W4382774814 hasConcept C98274493 @default.
• W4382774814 hasConceptScore W4382774814C121608353 @default.
• W4382774814 hasConceptScore W4382774814C126322002 @default.
• W4382774814 hasConceptScore W4382774814C150903083 @default.
• W4382774814 hasConceptScore W4382774814C203014093 @default.
• W4382774814 hasConceptScore W4382774814C207001950 @default.
• W4382774814 hasConceptScore W4382774814C2776694085 @default.
• W4382774814 hasConceptScore W4382774814C2777701055 @default.
• W4382774814 hasConceptScore W4382774814C2780110267 @default.
• W4382774814 hasConceptScore W4382774814C2780790343 @default.
• W4382774814 hasConceptScore W4382774814C2781303535 @default.
• W4382774814 hasConceptScore W4382774814C502942594 @default.
• W4382774814 hasConceptScore W4382774814C530470458 @default.

• next